A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures.
• Male or female adults aged 18 to 75 years at the time of signing the ICF.
• Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \>50% of the pons volume, with diffuse brainstem enlargement.
• Karnofsky Performance Status (KPS) score ≥ 60.
• Expected survival time ≥ 3 months.
Locations
Other Locations
China
Sun Yat-sen University Cancer Center
RECRUITING
Guangzhou
Contact Information
Primary
Yuanyuan Chen
chenyy2@sysucc.org.cn
202-87343543
Time Frame
Start Date: 2026-05-07
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 10
Treatments
Experimental: VRT106
VRT106
Related Therapeutic Areas
Sponsors
Leads: Guangzhou Virotech Pharmaceutical Co., Ltd.